Opinion/decision on a Paediatric investigation plan (PIP): Comirnaty, Tozinameran,Tozinameran / famtozinameran,tozinameran/ riltozinameran,raxtozinameran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0105/2024

EMEA-002746-PIP01-20-M03

EMEA-002736-PIP02-23

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0102/2024

EMEA-003569-PIP01-23

EMEA-003405-PIP01-23

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025

PSUSA/00001842/202410

EMEA-003313-PIP03-23

EMEA-003540-PIP01-23